MAGNENDO CORP: $17.3M Department of Health and Human Services Federal Award
Summary
MAGNENDO CORP, a private entity, received a $17.3M NIH grant for autonomous magnetic soft-continuum robots for stroke intervention. As the recipient is not publicly traded, there is no direct impact on stock markets. The contract supports advanced medical robotics research but does not signal near-term revenue for public companies.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.MAGNENDO CORP is private; no public tickers are affected.
- 2.The $17.3M NIH grant is for advanced medical robotics research.
- 3.No related legislation directly supports this contract's technology.
Market Implications
This contract does not create any direct market implications for publicly traded companies. The award is a research grant to a private entity, and no public company is identified as a beneficiary. Investors should not adjust positions based on this news.
Full Analysis
The Department of Health and Human Services, through the National Institutes of Health, awarded a $17.3M direct financial aid contract to MAGNENDO CORP for developing autonomous magnetic soft-continuum robots aimed at breaking physical limits in stroke intervention. The contract runs from July 2026 to June 2031, indicating a multi-year research and development effort. MAGNENDO CORP is a private company with no publicly traded equity, so this award does not directly affect any stock.
Because the recipient is private, no public company benefits directly from this contract. The technology area—soft robotics for medical applications—is emerging, but the award size is modest relative to the broader healthcare and robotics sectors. No publicly traded competitors or supply chain partners are identifiable from this award alone.
Reviewing related legislation, none of the listed bills share a specific objective or technology class with this contract. Bills such as S5236 (Medicaid mental health coverage) or S5237 (antibiotic resistance research) are in the healthcare sector but do not target stroke intervention or robotics. Thus, no legislative tailwind is directly tied to this award.
Supply chain effects are minimal; the contract is a direct grant to a single private entity for research, not a procurement contract requiring subcontractors. Historical patterns show that NIH small business innovation research (SBIR) and similar grants often lead to technology maturation but rarely cause immediate market shifts unless the recipient later goes public or licenses technology to a public company.
Overall, this contract is a routine research award with no direct public market implications. Investors should monitor MAGNENDO CORP for future developments, but no actionable stock moves are warranted from this news alone.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SIEMENS HEALTHINEERS ENDOVASCULAR ROBOTICS, INC.: $14.5M Department of Health and Human Services Federal Award
VERILY LIFE SCIENCES LLC: $14.1M Department of Health and Human Services Federal Award
UNIVERSITY OF MARYLAND, COLLEGE PARK: $76.1M National Aeronautics and Space Administration Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended, on Recoverable Critical Minerals and Materials
This memorandum invokes the Defense Production Act (DPA) Section 101 to declare that recoverable critical minerals and materials (such as black mass, end-of-life rare-earth magnets, and scrap) are essential to national defense and that the U.S. cannot meet defense needs without disrupting civilian markets. It directs the Secretary of Commerce to issue regulations and take actions—including priority contracts and supply-chain interventions—to rapidly expand domestic recovery and processing of these materials, while explicitly excluding copper scrap already covered by a separate proclamation.
Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materials
This executive order restricts waivers for foreign-sourced critical materials in defense contracts, effective January 1, 2027, and mandates that defense contractors map their supply chains from raw materials to end products, vet subcontractors for risks, and prohibit covered materials from unreliable foreign suppliers. It directs the Secretary of War to enforce strict compliance, including requiring mitigation plans for any non-compliant materials and establishing penalties for fraud or willful noncompliance.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Contract Details
Recipient
MAGNENDO CORP
Award Amount
$17,290,933
Awarding Agency
Department of Health and Human Services
Sub-Agency
National Institutes of Health
Contract Type
DIRECT PAYMENT FOR SPECIFIED USE, AS A SUBSIDY OR OTHER NON-REIMBURSABLE DIRECT FINANCIAL AID (C)
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →